<li>almotriptan<p>sertraline, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>bumetanide<p>bumetanide, sertraline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>carbamazepine<p>sertraline increases levels of carbamazepine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>celandine<p>celandine decreases effects of sertraline by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.</p></li><li>chlorpromazine<p>sertraline will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>codeine<p>sertraline decreases effects of codeine by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of codeine to active metabolite morphine.</p></li><li>dexfenfluramine<p>sertraline will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of sertraline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>dextromethorphan<p>sertraline will increase the level or effect of dextromethorphan by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>donepezil<p>sertraline will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>doxepin<p>sertraline will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>eletriptan<p>sertraline, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>encainide<p>sertraline will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>esmolol<p>sertraline increases levels of esmolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>ethacrynic acid<p>ethacrynic acid, sertraline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>fesoterodine<p>sertraline will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>flecainide<p>sertraline will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. Monitor the EKG in patients receiving concurrent flecainide and sertraline. Doses of flecainide may need to be reduced.</p></li><li>fluphenazine<p>sertraline will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>frovatriptan<p>sertraline, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>furosemide<p>furosemide, sertraline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>galantamine<p>sertraline will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>hydrocodone<p>sertraline decreases effects of hydrocodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of hydrocodone to active metabolite morphine.</p></li><li>lithium<p>sertraline, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.</p></li><li>loratadine<p>sertraline will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of sertraline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>mexiletine<p>sertraline will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>naratriptan<p>sertraline, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>panax ginseng<p>panax ginseng increases effects of sertraline by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>perhexiline<p>sertraline will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>perphenazine<p>sertraline will increase the level or effect of perphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of sertraline by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>prochlorperazine<p>sertraline will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>promazine<p>sertraline will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>promethazine<p>sertraline will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>propafenone<p>sertraline will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. Monitor the EKG in patients receiving concurrent propafenone and sertraline. Doses of propafenone may need to be reduced.</p></li><li>rizatriptan<p>sertraline, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan<p>sertraline, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan intranasal<p>sertraline, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan transdermal<p>sertraline, sumatriptan transdermal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>tolterodine<p>sertraline will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>torsemide<p>torsemide, sertraline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>trifluoperazine<p>sertraline will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>tropisetron<p>sertraline will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>zolmitriptan<p>sertraline, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li>